Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
Clinical Ophthalmology · 2023-05 · Volume 17 · 1287-1293
DOI: 10.2147/opth.s409822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ophthalmology, 2023-05. Verfasst von Ella H Leung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Georgia Retina, Atlanta, GA, USA. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Georgia Retina, Atlanta, GA, USA.
Zitieren
APA
Leung, E. H., Oh, D. J., Alderson, S. E., Bracy, J., McLeod, M., Perez, L. I., Bottini, A., Chin Yee, D., & Mukkamala, K. (2023). Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, Volume 17, 1287-1293. https://doi.org/10.2147/opth.s409822
Vancouver
Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology. 2023;Volume 17:1287-1293. doi:10.2147/opth.s409822
BibTeX
@article{Leung2023,
author = {Leung, Ella H and Oh, Daniel J and Alderson, Shannon E and Bracy, Joshlynn and McLeod, Mia and Perez, Litzi I and Bottini, Alexander and Chin Yee, David and Mukkamala, Krishna},
title = {Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration},
journal = {Clinical Ophthalmology},
year = {2023},
volume = {Volume 17},
pages = {1287--1293},
doi = {10.2147/opth.s409822}
}
EUVIMED